Wall Street brokerages expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce ($0.66) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.55) per share during the same quarter last year, which suggests a negative year over year growth rate of 20%. The firm is scheduled to announce its next quarterly earnings report on Friday, March 9th.
On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($2.82) per share for the current year, with EPS estimates ranging from ($2.84) to ($2.80). For the next financial year, analysts expect that the firm will report earnings of ($3.23) per share, with EPS estimates ranging from ($3.28) to ($3.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.19.
Separately, Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $20.25.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 10,000 shares of the stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 46.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of Corvus Pharmaceuticals by 29.3% in the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after purchasing an additional 2,105 shares during the period. New York State Common Retirement Fund raised its position in shares of Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after purchasing an additional 9,099 shares during the period. Alliancebernstein L.P. bought a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $175,000. California State Teachers Retirement System raised its position in shares of Corvus Pharmaceuticals by 121.2% in the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after purchasing an additional 8,200 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Corvus Pharmaceuticals by 338.4% in the second quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock valued at $188,000 after purchasing an additional 12,017 shares during the period. 83.39% of the stock is currently owned by institutional investors.
Corvus Pharmaceuticals (NASDAQ:CRVS) traded down $0.12 on Wednesday, reaching $10.39. 106,972 shares of the company’s stock were exchanged, compared to its average volume of 87,920. The stock has a market capitalization of $221.14, a PE ratio of -3.86 and a beta of -1.51. Corvus Pharmaceuticals has a 52-week low of $8.27 and a 52-week high of $22.14.
ILLEGAL ACTIVITY WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/analysts-anticipate-corvus-pharmaceuticals-inc-crvs-will-announce-earnings-of-0-66-per-share.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.